Marex Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,588
Closed -$485K 1359
2026
Q1
$458K Buy
+3,588
New +$448K ﹤0.01% 649
2025
Q4
Sell
-3,294
Closed -$378K 1160
2025
Q3
$330K Sell
3,294
-4,574
-58% -$412K ﹤0.01% 601
2025
Q2
$652K Buy
7,868
+3,058
+64% +$244K 0.01% 346
2025
Q1
$390K Buy
+4,810
New +$430K 0.01% 393
2024
Q4
Sell
-23,869
Closed -$2.36M 824
2024
Q3
$2.36M Buy
+23,869
New +$2.35M 0.05% 134
2024
Q1
Sell
-4,574
Closed -$408K 683
2023
Q4
$408K Sell
4,574
-10,323
-69% -$767K 0.02% 336
2023
Q3
$1.09M Buy
14,897
+11,255
+309% +$899K 0.15% 71
2023
Q2
$303K Buy
+3,642
New +$305K 0.05% 173

Other funds holding XBI

Marex Group's XBI Position: Q2 2026 in Review

Marex Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 3,588 shares — an estimated $485K sold.

Marex Group first reported a position in XBI in Q2 2023 and held it in 8 quarters. The position peaked at $2.36M in Q3 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Marex Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 3,588 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $485K.
  • Marex Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and held it in 8 quarters.
  • Marex Group's State Street SPDR S&P Biotech ETF position peaked at $2.36M in Q3 2024.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.